Trials / Active Not Recruiting
Active Not RecruitingNCT05583344
Phase 2b Study of GSK4532990 in Adults With NASH
17 β-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults With Nonalcoholic Steatohepatitis
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 284 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK4532990 | GSK4532990 will be administered. |
| DRUG | Placebo | Placebo will be administered. |
Timeline
- Start date
- 2023-01-02
- Primary completion
- 2026-01-31
- Completion
- 2027-04-05
- First posted
- 2022-10-17
- Last updated
- 2026-03-24
Locations
170 sites across 17 countries: United States, Argentina, Australia, Belgium, Canada, France, Greece, India, Italy, Japan, Mexico, Panama, Puerto Rico, South Korea, Spain, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05583344. Inclusion in this directory is not an endorsement.